Objectives: Current College of American Pathologists/ American Society of Clinical Oncology guidelines recommend cold ischemic time (CIT) of 1 hour or less for breast specimens to preserve biomarker expression, although some publications support an acceptable CIT of 4 hours or less. We retrospectively evaluated changes in estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) from biopsy to resection specimens that were triaged to optimize CIT.
For patients with invasive breast cancer, estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2/neu (HER2) have proven prognostic and predictive value 1 ; thus, evaluation of these biomarkers is standard of care for all new invasive, recurrent, and metastatic cancers. 2 In addition, ER testing is standard for new ductal carcinoma in situ (DCIS) diagnoses. 3 Although not required, PR testing (in combination with ER) on DCIS and ER/PR testing on pleomorphic lobular carcinoma in situ (pLCIS) are performed by some laboratories to help guide clinical management.
Because of their clinical importance in breast cancer, variables affecting ER, PR, and HER2 testing have been investigated and findings incorporated into College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) recommendations for testing. These recommendations outline standards for specimen adequacy, analyte selection, and many other important aspects of testing. Preanalytic variables, including cold ischemic time (CIT), are addressed in depth. 4, 5 CIT, or time from which tissue is removed from the patient to exposure to formalin, has been shown to affect ER, PR, and HER2 results. Specifically, delay to formalin fixation (DFF), or prolonged CIT, has been shown to cause decreased expression and false-negative results. [6] [7] [8] [9] Some publications support acceptable CIT of up to 4 hours, given the specimen is chilled, due to minimal reduction in specimen quality for biomarker evaluation. [9] [10] [11] However, 2010 CAP/ASCO guidelines recommend CIT of 1 hour or less. 4 Breast resections require incision for tumor to achieve adequate, timely fixation. 12 Thus, coordination between the operating room and pathology is imperative for optimizing CIT. We previously outlined a rapid triage protocol for breast resections that resulted in CIT of 4 hours or less for nearly all patients (2,323/2,362 [98.3%]) and 1 hour or less for many (1,845/2,362 [78.1%]), preserving prognostic and therapeutic biomarker testing while allowing for later, in-depth grossing. 13 In the current study, we sought to compare breast cancer biomarker results in the subset of these patients with controlled CIT of 4 hours or less and repeat ER, PR, and/or HER2 testing on tumors assessed on prior biopsy material.
Materials and Methods

Case Selection
Briefly, our previously described triage protocol involved rapid delivery of breast resections to the laboratory; an abbreviated gross assessment of the specimen, including incision, to allow adequate tumor exposure to formalin; and recording of excision time and time in formalin to calculate CIT. 13 Cases included in the current study were those from the prior cohort (consecutive breast resections from 2014-2016) that had undergone lumpectomy or mastectomy with prior biopsy for which one or more biomarkers (ER, PR, and/or HER2) were repeated on the same focus of cancer in the resection.
Clinicopathologic features evaluated included age, sex, diagnosis, stage, grade, prior and current procedures, absolute and categorical (≤1 hour vs >1 but ≤4 hours) CIT, reason (CAP/ASCO vs other) for repeat biomarker testing, biomarker(s) performed, biomarker results, and absolute and categorical differences in biomarker results.
Biomarker Analysis
Immunohistochemistry (IHC) was performed using antibodies directed against ER (clone SP1), PR (clone 1E2), and HER2 (clone 4B5) per manufacturer guidelines and evaluated using the US Food and Drug Administration-approved iScan Coreo System (Ventana Medical Systems). Tumors were interpreted as ER or PR negative if they had less than 1% nuclear staining and positive if they had 1% or more, with subcategorization as low positive if 1% to 9% and positive if 10% or more. HER2 IHC was interpreted semiquantitatively (0-1+, negative; 2+, equivocal; or 3+, positive), and fluorescence in situ hybridization (FISH) using the PathVysion (Abbott Molecular) dual-probe assay was reflexively performed if HER2 IHC was equivocal, and both were scored in accordance with 2013 CAP/ASCO guidelines. 5 Full tissue sections were used for all analyses.
Meaningful Biomarker Differences
Meaningful difference in biomarker status, or unexpected categorical change with potential to elicit therapy change, was also analyzed. For HER2, this included cases from which status changed from positive to negative or vice versa. We chose to examine meaningful ER/PR differences in multiple ways, with one including those with change from low positive/positive to negative or vice versa, another also including cases with change from low positive to positive or vice versa, and another just looking at those with change from negative/low positive to positive, as recent studies support low positive (1%-9%) expression (in HER2-negative tumors) to be more in keeping with ER/PR negativity with regard to hormonal therapy response and survival outcomes. 14
Statistical Methods
Descriptive statistics are presented for continuous and categorical variables. Simple logistic regression was used to look for an association between meaningful change and clinicopathologic features. Fisher exact test was used to determine if there was any difference in method by which HER2 changed for those with change in HER2 status. Linear regression modeling was used to examine the difference between biopsy and resection ER and PR results. P ≤ .05 was considered statistically significant. All analyses were conducted using SAS (version 9.4; SAS Institute).
Results
Patients
In total, 2,821 specimens from 2,344 patients were reviewed, of which 295 (10.5%) had lumpectomy or mastectomy for prior malignant diagnoses of pLCIS, DCIS, and/or invasive carcinoma; CIT of 4 hours or less; and repeat ER, PR, and/or HER2 studies with a prior biopsy comparison ❚Figure 1❚.
Patients 
Biomarker Differences
Categorical biomarker change was seen in 10 (17.9%) of 56 patients with repeat ER/PR and 38 (13.3%) of 285 with repeat HER2 analysis. Five (1.8%) had a meaningful difference in HER2 status. For ER/PR, five (8.9%) had a status change from low positive/positive to negative or vice versa and five (8.9%) from low positive to positive or vice versa ❚Table 3❚. Of 46 with no categorical change in ER/ PR status, 18 (39.1%) were ER/PR negative, three (6.5%) low positive, and 25 (54.4%) positive. This contrasts with the group with ER/PR change in which nine (90%) of 10 had one or more low-positive results. Example cases with biomarker status change are shown in ❚Image 1❚.
Meaningful biomarker change was not significantly associated with specific clinicopathologic feature(s) in all analyses. In addition, subset analysis showed no significant difference in testing method (IHC vs FISH) by which meaningful HER2 change occurred.
Discussion
Recent attention to the negative impacts of DFF, or prolonged CIT, on breast biomarkers has resulted in revision of CAP/ASCO optimal handling requirements to include recording of CIT and recommendations for CIT of 1 hour or less. 4 A recent review article by Khoury 15 outlines major studies examining the effects of DFF, which overall show a decline in the expression of breast cancer biomarkers with increasing DFF, several of which he and colleagues have contributed to the published literature. [6] [7] [8] 16 In this review, studies are divided into prospective, in which multiple portions of the same tumor were subjected to variable DFF, 6, 8, 11, [16] [17] [18] and retrospective, in which biopsy and resections with known CIT were compared. 9, 10, 19, 20 Prospective studies best confirm true reductions in biomarker expression with DFF by controlling for most analytic variables but still have (minimized but potential) confounders of sample selection and tumor heterogeneity. However, most prospective studies to date have been relatively small, with studied cohorts ranging from one to 25 tumor samples. [6] [7] [8] 11, [16] [17] [18] 21 Comparatively, retrospective studies portend more confounding analytic variables but offer larger study populations as well as insight into patient impact of DFF on biomarker analysis.
Pekmezci et al, 20 in a retrospective study, compared biopsy and resections in which CIT was not tracked in the latter and thus presumed to be more than 1 hour. Subsequently, they saw no significant difference in HER2 results but observed a statistically significant status change from positive to negative on resections in 3.4% (5/149) and 7.1% (9/126) for ER and PR expression, respectively; this was predominantly seen in tumors with low biopsy expression. 20 Other retrospective studies by Li et al, 9 Portier et al, 10 and Neumeister et al 19 compared biopsy and resection material with known CIT, the latter two using a tissue microarray (TMA) created at the University of Rochester Medical Center, where similar attention has been given to specimen triage for accurate CIT measurement. 22 ❚Figure 1❚ Breast resection specimens with cold ischemic time (CIT) 4 hours or less and repeat estrogen receptor (ER), progesterone receptor (PR) and/or HER-2/neu (HER2) immunohistochemistry (IHC) performed. DCIS, ductal carcinoma in situ; pLCIS, pleomorphic lobular carcinoma.
Methods of specimen retrieval and processing are also detailed in the Li et al 9 study, but since this study occurred at the University of Texas MD Anderson Cancer Center, where there is frequent utilization of intraoperative assessment, estimates for specimen imaging and other evaluation are used in the calculation of CIT. 9 Li et al 9 examined a cohort of 97 patients with CIT ranging from 25 to 357 minutes. Using 25% difference in ER staining to define change, they observed nonstatistically significant declines in ER expression with CIT of more than 2 hours. 9 Neumeister et al 19 used a TMA with samples from 93 patients with CIT ranging from 25 to 415 minutes. Using the automated quantitative analysis method of quantitative immunofluorescence, they also observed nonstatistically significant declines in ER/PR expression with increasing DFF and no change in HER2 expression. 19 Finally, Portier et al 10 used a TMA with 84 tumors (after exclusions) with CIT of 27 to 385 minutes (<1 hour, n = 45; 1-2 hours, n = 27; 2-3 hours, n = 6; >3 hours, n = 6). They evaluated HER2 by IHC, INFORM dual in situ hybridization, and FISH and noted a significant degradation in FISH signal intensity at CIT of more than 3 hours but no significant changes in HER2 status by any method for all CIT cohorts. 10 The current retrospective study is the largest to date, with 61 tumors from 56 patients having repeat ER/PR and 285 having repeat HER2 analysis. In all cases, CIT was minimized via special triage protocol and was 4 hours or less. Of note, our cohort was highly selected for those with which there was a CAP/ASCO indication for repeat analysis (250/295 [84.7%]), making them more likely to show variation in biomarker expression due to other variables such as tumor heterogeneity and limited tumor on biopsy. Despite this, we saw infrequent changes that were likely to result in an unexpected, meaningful status change.
Close examination of our cases with ER/PR change ( Table 2) shows that there was only one case that changed dramatically, a case of invasive ductal carcinoma with metaplastic features that was ER 0% and PR 4% on the biopsy specimen that increased to 45% PR expression on resection. Notably, most (9/10 [90%]) with ER/PR change had at least one low-positive value, with all other measurements being either negative or just above the threshold of low positive to positive (10%-15% expression). In addition, we noted declines in ER/PR expression in seven (12.5%) of 56 patients but also saw increased expression in three (5.4%) of 56 from biopsy to resection.
Regarding HER2, all five (1.8%) cases with meaningful HER2 change in this study had at least one equivocal IHC value and required testing by FISH for final determination. Of note, one case had only microinvasive carcinoma on both biopsy specimen and resection, so it could be argued that this case may have had two invasive carcinoma clones, with different expression patterns, arising in extensive DCIS. It is also noteworthy that during this time period CAP/ASCO HER2 recommendations stated that HER2 "must" be repeated on all grade 3 invasive carcinomas that were negative on a prior biopsy, 5 wording that has been revised to "may" in a recent focused update. 23 In this selected cohort, we saw infrequent biomarker expression change between biopsy and resection specimens with CIT of 4 hours or less. No specific feature was associated with "meaningful" ER/PR and/or HER2 status change, no matter how it was defined, including absolute and categorical CIT of 1 hour or less vs CIT of more than 1 hour but 4 hours or less. Thus, these findings may support the conclusions of others that CIT of up to 4 hours may be acceptable. In addition, infrequent meaningful HER2 status change supports current CAP/ASCO recommendations that not all grade 3 invasive carcinomas with HER2-negative biopsy testing require repeat evaluation on resection material. 4, 23 Finally, our findings also support that repeat ER/PR analysis on resection material may be helpful in guiding clinical management in patients with low-positive biopsy expression, given adequate specimen triage and processing practices are in place to guarantee accurate and timely CIT to preserve biomarker expression.
We have used a triage protocol in which the tumor is incised to allow adequate tumor exposure to formalin, 13 a similar protocol to that described by Hicks et al. 22 However, in his review article, Khoury 15 also supports injection of the tumor with formalin to minimize DFF, especially when there is no pathologist/pathologist assistant available for triaging or when the specimen must be transported within or between institutions for grossing/processing. Tissue procurement programs can also aid in optimal handling, as they can help facilitate rapid specimen delivery and incision for biobanking evaluation and subsequent formalin exposure.
The negative effects of prolonged CIT on biomarker expression have also been shown to be minimized with refrigeration, as in the prospective study by Yildiz-Aktas et al, 11 in which 23 paired room temperature and refrigerated (4°C) resection samples were subdivided and allowed to undergo variable DFF. In their study, ER and PR, as assessed by H-score and compared with corresponding biopsy expression, had statistically significant decreased expression for nonrefrigerated samples only, at 3 and 24 hours, respectively. 11 Sewart et al 24 also studied the effects of refrigeration (4°C) vs ❚Image 1❚ A-D, Example case 1. Invasive lobular carcinoma, modified Bloom-Richardson (mBR) grade 2. On biopsy specimen (not pictured), the human epidermal growth factor receptor 2 (HER2) result was 2+ equivocal, while the mastectomy (A-D) showed morphologic tumor heterogeneity with 3+ positive staining with HER2 (A, H&E, ×2; B, immunohistochemistry [IHC], ×2; C, H&E, ×4; D, IHC, ×4). snap-freezing on 36 breast samples (within 30 minutes from removal from the patient) and found no significant differences in RNA, DNA, and protein quality. 24 Comparably, Viana et al 25 found CIT of just 45 minutes (as compared with ≤30 minutes) at room temperature to have significant negative impacts on RNA quality. 25 These findings support that rapid chilling of specimens reduces negative effects of DFF, which is more easily done (vs formalin injection) when lacking on-site pathology.
As noted above, cases included in this study may have more likely had biomarker expression variation due to tumor heterogeneity since many underwent repeat evaluation for CAP/ASCO indications. Evaluation was also performed at various time points; thus, analytic variables related to processing and staining may have also had an impact on biomarker changes. In addition, other unstudied patient/tumor variables may have also had impact. For example, resection specimens, depending on the difficulty and/or length of the surgery, are variably influenced by warm ischemia time, or time from loss of tumor blood supply to time of removal from the patient, which results in accelerated enzymatic degradation due to the warm environment of the body. Additional unstudied features such as tumor infarction, necrosis, and alterations due to presurgical interventions can also affect biomarker expression.
❚Image 1❚ (cont) E-H, Example case 2. Invasive ductal carcinoma, mBR grade 3. On biopsy specimen, the invasive carcinoma was estrogen receptor (ER) negative (E, H&E, ×30; F, IHC, ×30), while the lumpectomy showed focal (1.2%, weak) ER positivity (G, H&E, ×30; H, IHC, ×30).
